Integration of a multimeric STAT consensus site into the adenoviral genome to interfere with IFN signaling represents a novel concept to improve oncolytic virotherapy. [PDF]
Wang D +7 more
europepmc +1 more source
Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells. [PDF]
Gellert S +5 more
europepmc +1 more source
The Role of Viral Dynamics and Infectivity in Models of Oncolytic Virotherapy for Tumours with Different Motility. [PDF]
Morselli D, Frascoli F, Delitala ME.
europepmc +1 more source
Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific immunity in a DC-activation-dependent manner. [PDF]
Hanesch L +4 more
europepmc +1 more source
The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management. [PDF]
Nizamutdinov D +7 more
europepmc +1 more source
Can a mosquito-borne virus become a cancer therapy? rethinking Getah virus through the lens of oncolytic virotherapy. [PDF]
Efa BB, Antwi-Osei Jnr J.
europepmc +1 more source
Harnessing oncogenic signaling to enhance oncolytic virotherapy: Lessons from EPAC-encoding vaccinia virus. [PDF]
Boulton S, Singh S, Bell JC.
europepmc +1 more source
Oncolytic virotherapy and tumor microenvironment modulation. [PDF]
Rivera-Orellana S +11 more
europepmc +1 more source
Engineering systemic oncolytic virotherapy through immune-compatible delivery and programmable tumor cell death. [PDF]
Chen X, Chen Y, Ping Y.
europepmc +1 more source
Targeting collagen to enhance oncolytic virotherapy outcome in gastric cancer patients. [PDF]
Soni H.
europepmc +1 more source

